Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of 53,417 shares of common stock, 34,684 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 34,426 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to Sung H. Lee, the Company’s Executive Vice President and Chief Financial Officer, whose employment commenced on May 8, 2024, as a material inducement to his employment. The Company also granted stock options to purchase an aggregate of 93,525 shares of common stock, 60,724 RSUs that will be settled in shares of common stock upon vesting and 40,610 PSUs that, if earned, will be settled in shares of common stock upon vesting to an additional 12 employees, whose employment commenced in May 2024, as a material inducement to their employment. The RSUs wil
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsGlobeNewswire
- Cytokinetics says potential acquirer walked away [Seeking Alpha]Seeking Alpha
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at B. Riley from $122.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
CYTK
Earnings
- 5/8/24 - Miss
CYTK
Sec Filings
- 6/17/24 - Form 144
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- CYTK's page on the SEC website